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Improved results of lung transplantation for 
patients with cystic fibrosis 
Patients with cystic fibrosis pose particular challenges for lung transplant surgeons. Earlier reports 
from North American centers suggested that patients with cystic fibrosis were at greater isk for 
heart-lung or isolated lung transplantation than other patients with end-stage pulmonary disease. 
During a 31A year period, 44 patients with end-stage lung disease resulting from cystic fibrosis 
underwent double lung transplantation at this institution. During the same interval, 18 patients with 
cystic fibrosis died while waiting for lung transplantation. The ages of the recipients ranged from 8 
to 45 years, and mean forced expiratory volume in 1 second was 21% predicted. Seven patients had 
Pseudomonas cepacia bacteria before transplantation. Bilateral sequential implantation with omen- 
topexy was used in all patients. There were no operative deaths, although two patients required 
urgent retransplantation because of graft failure. Cardiopulmonary bypass was necessary in six 
procedures in five patients and was associated with an increased blood transfusion requirement, 
longer postoperative ntilation, and longer hospital stay. Actuarial survival was 85% at I year and 
67% at 2 years. Infection was the most common cause of death within 6 months of transplantation 
(Pseudomonas cepacia pneumonia was the cause of death in two patients), and bronchiolitis 
obliterans was the most common cause of death after 6 months. Actuarial freedom from development 
of clinically significant bronchiolitis obliterans was 59% at 2 years. Results of pulmonary function 
tests improved substantially in survivors, with forced expiratory volume in 1 second averaging 78% 
predicted 2 years after transplantation. Double lung transplantation can be accomplished with 
acceptable morbidity and mortality in patients with cystic fibrosis. (J THORAC CARDIOVASC SURG 
1995;109:224-35) •
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Cyst i c  fibrosis (CF) is the most common lethal 
genetic disease of the white population. Although 
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the disease affects several organ systems, more than 
95% of affected individuals die of pulmonary insuf- 
ficiency. ~ It is estimated that up to 400 patients with 
CF die annually in the United States alone. 2
The past decade saw remarkable advances in 
understanding the pathophysiology of CF, including 
identification of the chloride channel abnormality 3 
and the responsible gene 4 and creation of a trans- 
genic mouse with CF. 5 Expected survival has in- 
creased from 10 years in the 1960s to 28 years in 
1990. 2 Promising new therapies that have become 
available for the treatment of patients with CF- - for  
example, ameloride, 6 uridine triphosphate 7 and de- 
oxyribonuclease s may enhance chances of pro- 
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longed survival. There is speculation that "gene 
therapy" may provide the ultimate cure for patients 
with CF. 9 Nevertheless, thousands of patients with 
CF will likely die of the devastating effects of severe 
bronchiectasis caused by inspissated infected pulmo- 
nary secretions. For these patients, replacement of 
infected, irreversibly damaged lungs by transplanta- 
tion may offer improved length of survival and 
quality of life. 
Initial reports of heart-lung transplant efforts for 
patients with CF in North America were discourag- 
ingJ ° Increasing experience and modifications of 
technique have led to improved prospects for pa- 
tients with CF undergoing lung transplantation. In
this report, we summarize the results of double lung 
transplantation at one institution in patients with CF 
with end-stage lung disease. 
Patients and methods 
Since January 1990, 81 patients have undergone 85 
isolated lung transplant procedures at the University of 
North Carolina Hospitals. The 44 patients with CF from 
this group form the basis of this report. 
Patient selection. Selection criteria for pulmonary 
11 transplantation have been published previously ; the 
criteria for patients with CF are as follows: 
Age less than 50 years 
Life expectancy 18 to 24 months 
No significant renal or hepatic disease 
No evidence of malignancy for more than 5 years 
Ambulatory and able to participate in rehabilitation 
program 
Ability to understand and comply with a complex 
medical regimen 
Psychologic stability 
Previous pleural procedures acceptable 
No panresistant organisms in sputum 
Data with respect to pulmonary function, pulmonary 
cultures, history of hospitalization, and relevant psycho- 
social history were obtained from referring physicians. 
Prospective candidates were evaluated to identify other 
organ system dysfunction--especially renal, cardiac, or 
hepatic dysfunction--that might preclude a successful 
outcome of transplantation. 12 Candidates were evaluated 
by a team consisting of psychologists, social workers, and 
physicians experienced in the management of patients 
with CF. Thereafter, a consensus was reached regarding 
the suitability of candidates. In general, in the absence of 
contraindications, transplantation was offered to patients 
with a life expectancy of less than 24 months without a 
transplant. Patients with confirmed panresistant organ- 
isms are currently not considered candidates. 
Estimating life expectancy without transplantation is 
difficult, but certain objective parameters such as hyper- 
carbia, increasing oxygen requirement, and forced expira- 
tory volume in 1 second of less than 30% predicted are 
associated with a poor prognosis in CF.  13 Other concerns 
include the requirement for more frequent hospitaliza- 
tions and the loss of functional capacity. In an earlier 
analysis of our CF referrals, 41 of 57 referred candidates 
(72%) were found to be acceptable for transplantation; 
four of these chose not to be listedJ 4 During the period in 
which these 44 patients have undergone transplantation, 
18 additional patients with CF died waiting for lung 
transplantation. 
Listed candidates are required to relocate close to our 
transplant center and to participate in a preoperative 
program of pulmonary rehabilitation, consisting of moni- 
tored, graded aerobic exercise. Ideally, listed patients 
participate in the rehabilitation program for 2 to 3 months 
before transplantation. 
Transplantation technique. Lungs were retrieved from 
donors through a median sternotomy. After infusion of 
500 ~g prostaglandin E1 (Prostin, Upjohn, Kalamazoo, 
Mich.) into the pulmonary artery, donor lungs were 
flushed with modified Euro-Collins solution (80 ml/kg). 
All recipients received preoperative and perioperative 
antibiotic prophylaxis tailored to the most recent sputum 
cultures and sensitivities, continued for a mean of 10 days 
after the operation. 
The transplantation technique first outlined by Pasque 
15 16 and associates, described in more detail elsewhere, has 
been used for patients with CF. The operation is per- 
formed through an anterior bilateral thoracosternotomy, 
or "clamshell" incision, made through the fourth or fifth 
intercostal space, with sequential removal and implanta- 
tion of both lungs. A preoperative quantitative radionu- 
clide perfusion scan identifies the lung with the least 
perfusion, which is removed first. Cardiopulmonary b - 
pass (CPB) is deliberately avoided in general, but it is used 
when necessitated byinadequate ventilation or right heart 
failure. Bronchial omentopexy is performed, with omen- 
turn mobilized through a midline laparotomy, based on 
the gastroepiploic artery, delivered into the chest hrough 
a substernal tunnel, then split to wrap both anastomoses. 
We have found bronchial healing to be superior with 
end-to-end anastomosis and omentopexy, 17 compared 
with the telescoping technique first described by Calhoon 
and colleagues, i  
Strategies to minimize contamination of the pleural 
space have been devised. Use of a double-lumen endotra- 
cheal tube reduces the risk of cross-contamination be- 
tween a native CF lung and the newly implanted graft. 
During explantation of the native lung, the bronchus is 
clamped istal to the line of division to reduce egress of 
purulent secretions, and the open airway and empty 
pleural space are irrigated with povidone-iodine (Beta- 
dine) solution after pneumonectomy before implantation. 
A bronchoscope is used after transplantation to aspirate 
any purulent secretions. 
Patients were not excluded because of prior thoracic 
surgical procedures. One patient had a previous lobec- 
tomy for hemoptysis; five had pleurodesis (one pleurec- 
tomy, one talc poudrage, and three mechanical brasions) 
for pneumothorax; and three had prior chest tubes (one 
for an empyema). 
Immunosuppression. Postoperative immunosuppression 
consisted of cyclosporine (Cyclosporin A; Sandoz, Basel, 
Switzerland), begun intravenously in the operating room; 
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Table I. Demographics ofCF recipients and donors 
Variable Recipient Donor 
Age (yr) 23.2 _+ 1.2 (8-45) 26.9 -+ 2.0 (4-52) 
Weight (kg) 42.8 4- 1.5 (20-68) 63.4 -+ 2.6 (20-95) 
Height (era) 160 _+ 2.2 (114-185) 168 -+ 2.6 (112-200) 
Sex (M/F) 20/24 23/21 
Weight for height 76 + 1.6 (58-106) 
(%) 
Donor/recipient weight ratio (mean) 1.5 -+ 0.05 (0.9 to 2.1). 
azathioprine (2 mg/kg); and antilymphocyte globulin, ini- 
tially University of Minnesota antilymphoblast globulin, 
15 mg/kg per day, and more recently Atgam (Upjohn). 19 
Systemic steroids were generally withheld until 2 weeks 
after transplantation, when prednisone was introduced at 
a dose of 0.5 mg/kg per day. Systemic steroids were 
reduced gradually to a dose of 15 mg every other day in 
adults 1 year after transplantation. Because oral cyclospo- 
rine is poorly absorbed in patients with CF, ketoconazole 
was routinely administered concomitantly to reduce me- 
tabolism of cyclosporine. 2° 
Episodes of acute rejection were treated with bolus 
intravenous methylprednisolone (15mg/kg for 1 to 2 days, 
reduced to 7.5 mg/kg, total therapy 3days). Rejection was 
diagnosed on the basis of transbronchial lung biopsy, 
according to published criteria, 21 or on clinical grounds, 
such as pyrexia or altered gas exchange, with or without 
pulmonary infiltrate on chest radiograph, in the absence 
of pulmonary infection, a9 All patients except one were 
treated for rejection within the first 2 weeks. 
Intraoperative management. General anesthesia for 
recipients was induced with fentanyl and maintained with 
isoflurane. Intubation with a left-sided ouble-lumen tube 
was routine for adults and large children. Recipients 
judged to be too small for a double-lumen tube were 
managed with a single-lumen endotracheal tube and 
bronchus-blocking balloons. Airway maintenance with 
suction is imperative throughout the operation, and occa- 
sionally bronchoscopy for airway toilet is necessary to 
allow for adequate ventilation. Obstruction of the left 
upper lobe orifice with the distal balloon of the double- 
lumen tube is a frequent occurrence, resulting in hypox- 
emia. 
Postoperative management. Patients were extubated 
when pH could be maintained in the normal range and 
oxygenation was adequate. Bronchoscopy, transbronchial 
biopsy, and bronchoalveolar l vage were performed at 1 
week, 3 weeks, and every 3 months for the first year after 
the operation and when indicated clinically to investigate 
a radiographic abnormality, altered gas exchange, or 
unexplained fever. Bronchoscopy was delayed uring the 
first week after transplantation if treatment for rejection 
had been initiated on clinical grounds. 
After discharge from the hospital, patients continued to 
participate in a rehabilitative program of monitored aer- 
obic exercise, which afforded an opportunity for close 
outpatient follow-up. The duration of participation in 
postoperative r habilitation depended on progress; pa- 
tients were advised to expect o remain in the geographic 
area of the transplant center for 2 months after hospital 
discharge. 
Lung function and other measurements. Percent 
forced vital capacity (FVC) and percent FEV a were 
calculated after measurement of FVC and FEV 1 by means 
of standard nomograms. Six-minute walk tests (the dis- 
tance walked in 6 minutes) were performed when patients 
were seen for evaluation and at intervals before and after 
the operation. Percent ideal body weight was calculated 
for each recipient. 22 
Statistics. Numeric results are expressed as mean + 
standard error of the mean. Comparisons were made with 
Student's t test or analysis of variance where appropriate. 
Results 
Since October 1990, 44 patients have undergone 
double lung transplantation for CF at our institu- 
tion. The demographics of the transplantation co- 
hort are summarized in Table I. Two male patients 
survived brief periods of ventilatory support before 
being evaluated and listed. The condition of four 
other patients deteriorated while they were awaiting 
transplantation after being listed, necessitating ven- 
tilator support for 7 to 19 days before transplanta- 
tion. These patients underwent successful transplan- 
tation during ventilator support. 23 Eighteen listed 
patients have died awaiting transplantation. Waiting 
time has increased in each year of the program (Fig. 
1). 
Organisms identified in respiratory tract cultures 
in patients before transplantation were representa- 
tive of the spectrum of organisms een in patients 
with CF. All Pseudomonas species were resistant o 
several antibiotics, but none were determined to be 
pan-resistant in vitro at the time of evaluation for 
transplantation and listing. Eight patients harbored 
Pseudomonas cepacia, three had nontuberculous 
Mycobacterium, and Aspergillus was recovered from 
24 patients. 
Operative and postoperative data are presented 
in Table II. Because the lungs are implanted se- 
quentially, ischemic times are presented for each 
lung. The additional ischemic time for the second 
lung represents the time for extraction of the re- 
maining native lung and implantation of the second 
graft. 
CPB was required on six occasions, usually be- 
cause of inability to oxygenate associated with re- 
fractory respiratory acidosis. CPB was associated 
with a larger blood transfusion requirement and 
with our only two cases of renal failure necessitating 
temporary dialysis after the operation. In two in- 
stances, substantial hemorrhage was related to 
lung abscesses of the upper lobe that involved the 
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Fig. 1. Waiting time after listing for patients with CF at University of North Carolina Hospitals, by year. 
The number of transplantations performed ineach calendar year is shown in parentheses. One patient was 
excluded in 1991 because he was transferred from a heart-lung list with a 3-year wait accumulated. 
chest wall to such an extent hat the pleural space 
was totally obliterated; both patients were unable to 
tolerate one-lung anesthesia, necessitating institu- 
tion of CPB. CPB was also associated with a longer 
requirement for postoperative ventilation, with a 
mean of 6 -+ 2.5 days in patients requiring CPB 
(excluding the patient requiring urgent retransplan- 
tation), compared with a mean of 1.8 + 0.26 days in 
patients who did not require CPB (p < 0.0005, t 
test). 
Because of the size discrepancy between donors 
and CF recipients (see Table I), size reduction 
procedures were used after transplantation i  nine 
patients. These procedures consisted of right middle 
lobectomy or nonanatomic resections with a TA 90 
stapler (United States Surgical Corporation, Auto 
Suture Company Division, Norwalk, Conn.), excis- 
ing the lingula, the apical portion of the lung, or a 
portion of the lung base posteriorly. Analysis of the 
impact of this pneumoreduction strategy has con- 
firmed that the reduced sized lungs more closely 
conformed to predicted recipient otal lung capacity 
and had no adverse impact on measurable spiromet- 
ric volumes after transplantation. 24 
All patients have survived the operation to be 
discharged from the hospital ambulatory and with- 
out supplementary oxygen. Two patients required 
retransplantation for acute graft failure on postop- 
erative days 8 and 13, respectively. Both survived 
after protracted hospital courses. Actuarial survival 
was 86% at 1 year and 67% at 2 years (Fig. 2). 
Deaths have arbitrarily been classified as early 
Table II. Perioperative data 
Ischemic time (min) 
First lung 311 _+ 9.4 
Second lung 470 _+ 13 
Blood use in operating room 
(units packed cells) 
With CPB (n = 6) 
Mean 21.5 _+ 1.9 
Range 15-28 
Without CPB (n = 38) 
Mean 6.05 - 0.6* 
Range 1-17 
Duration of ventilation (days) 
Mean 2.2 +- 0.4 
Range 1-13 
Median 1 
Hospital stay (days) 
Mean 28 - 3.3 
Range 14-129 
Median 21 
*p < 0.0001. 
(within 6 months of transplantation) and late (be- 
yond 6 months), and the causes are outlined in 
Table III. 
For purposes of discussion, complications have 
been grouped as surgical, medical, and infectious. 
Postoperative complications (exclusive of infection) 
are given in Table IV. Unilateral phrenic nerve palsy 
was observed in three patients early in the series. 
This is thought o be related to the use of rigid metal 
retractors on the mediastinum to improve exposure 
of the hilum. Since abandoning the use of metal 
retractors and using only a hand instead, we have 
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Fig. 2. Actuarial survival (Kaplan-Meier) of patients with CF having double lung transplantation. (Data 
--- 95% confidence limits.) 
Table III. Causes of death 
No. 
Early (<6 mo after transplantation) 
Pneumonia (Pseudomonas cepacia) 2 
Unexplained CNS death 1 
Late (>6 mo after transplantation) 
Obliterative bronchiolitis 6* 
CMV pneumonia 1 
Lymphoma 1 
Suicide 1 
*Noncompliance contributed totwo of these deaths. 
seen only one additional case of phrenic nerve paresis. 
We believe that the retraction used to expose both 
pleural spaces likely places the phrenlc nerves under 
some traction, setting the stage for neuropraxia if
additional retraction is applied to the pericardium. 
Bronchial healing has not been a cause of major 
morbidity in this subgroup of patients. Three in- 
stances of partial bronchial disruption have been 
observed bronchoscopically. Two of these were con- 
tained, but a bronchopleural fistula developed in 
one patient, necessitating percutaneous drainage of 
a cavity. All bronchi healed without stenosis. One 
stricture developed in the bronchus intermedius of 
the oldest recipient in the series, distal to a well- 
healed anastomosis. This was treated with insertion 
of a Dumon silicone rubber stent (Bryan Corp., 
Woburn, Mass.). 25 Healing of the skin incisions, and 
in particular the transverse sternotomy, has been 
problematic n only a small number of patients. One 
patient had a ventral hernia associated with postop- 
erative portal hypertension and ascites, and one 
Table IV. Complications 
No. 
Surgical 
Graft failure necessitating retransplantation 2 
Unilateral phrenic nerve paresis 3 
Bronchial dehiscence 
Contained (no air leak) 2 
With air leak 1 
Airway stricture (stent) 1 
Wound problems 
Sternal wound infection 2 
Sternal dehiscence necessitating reclosure 1 
Ventral hernia* 1 
Axillary vein thrombosis 6 
Gastrointestinal complications 
Gastric atony 7 
with bezoar 6 
Bowel obstruction/meconium leus equivalent 4 
Cholelithiasis after transplantation 2 
Choledocholithiasis after transplantation 1 
Pericarditis (staphylococcal) 1 
Medical 
Renal failure (temporary dialysis) 2 
CNS event 
Cerebrovascular ccident 1 
Unknown high intracranial pressure 1 
Seizures, new 12 
Ascites, related to portal hypertension* 1 
"Difficult" diabetes 8 
Posttransplantation lymphoproliferative disorder 2 
Osteoporosis resulting in spontaneous fractures 1 
*Related complications i  the same patient. 
other patient required rewiring of the sternotomy 
for early breakdown. Two or three sternal wires 
were used for closure in adult patients; heavy 
braided suture was used in pediatric patients. 
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Twelve patients have had grand mal seizures after 
transplantation. In three instances, cerebral abnor- 
malities were identified on computed tomographic 
scan after the first seizure and were believed to be 
contributory: one patient had an embolic event; one 
had an ischemic focus thought o be related to high 
preoperative carbon dioxide tension despite me- 
chanical ventilation; and one patient had several 
postoperative watershed infarcts, probably resulting 
from intraoperative hypotension and blood loss 
related to an abscess of the upper lobe involving the 
chest wall. In several patients the seizures were 
usually associated with elevated systemic blood pres- 
sure. One seizure disorder was unmasked uring a 
posttransplantation bronchoscopic study when a 
large dose of intraairway lidocaine had been admin- 
istered. Two other cases became apparent after 
treatment of rejection with bolus steroids. The com- 
plication of posttransplantation epilepsy not associ- 
ated with structurally identifiable brain lesions in 
our patients having lung transplantation has been 
seen only in lung recipients with CF and is particu- 
larly troublesome to treat, because phenytoin en- 
hances cyclosporine metabolism, further complicat- 
ing the dosing of this drug in these patients. 
Infectious complications are summarized in Table 
V and are reported, both by number of patients and 
number of courses of therapy, as events necessitat- 
ing antibiotic therapy. Infection of the graft was 
common. Bronchitis, defined as airway purulence 
without radiographic pneumonitis or consolidation, 
necessitating therapy is a frequent problem in pa- 
tients with obliterative bronchiolitis. Pneumonia (di- 
agnosed clinically or radiographically) was treated in 
18 patients on 42 occasions. Two patients have died 
of Pseudomonas cepacia pneumonia, which became 
apparent several weeks to months after transplanta- 
tion, One patient had persistent fever, and a Pseudo- 
monas cepacia mediastinal abscess was found 2 
months after transplantation. Despite percutaneous 
drainage, a necrotizing pneumonia of the right 
upper lobe developed. This was surgically resected 
as a sleeve right upper lobectomy. This airway 
anastomosis healed, but multiple pulmonary ab- 
scesses and bilateral necrotizing Pseudomonas cepa- 
cia pneumonia developed, resulting in the patient's 
death 31/2 months after transplantation. Pseudomo- 
nas cepacia has been a recognized cause of increased 
morbidity after double lung transplantation for CF 
at other centers. 26 
A clinical diagnosis of sinusitis was made in 17 
patients on 29 occasions. Five patients have had 
Table V. Infectious complications: indications for 
posttransplantation treatment with antibiotics 
Indication Patients (n) Courses (n) 
Bronchitis 27 60 
Pneumonia 18 42 
Sinusitis 17 29 
Bacteremia 10 11 
Fever, no organism or site 7 8 
Nontuberculous Mycobacteria 2 2 
Fungal or yeast infection 6 8 
CMV disease 27 44 
Varicella 2 2 
Herpes simplex virus 1 1 
surgical sinus drainage, all after transplantation. 
Bacteremia has been documented in five patients, 
proved to be "line related" in two. 
Cytomegalovirus (CMV) disease is a common 
occurrence. Twenty-seven patients have been 
treated on 44 occasions with gancyclovir for CMV 
disease. Only three patients had serious CMV pneu- 
monia necessitating supplemental oxygen; one of 
these died without benefit of mechanical ventilation. 
We abandoned a policy of matching CMV-negative 
recipients to CMV-negative donors after the sixth 
patient in the series. We have not found gancyclovir 
prophylaxis to be efficacious in lung transplant re- 
cipients. 27 
Despite the purulent nature of the end-stage lung 
disease in these patients, only two instances of 
empyema have occurred, one in a patient with 
Pseudomonas cepacia. There have been two sternal 
wound infections. One of them, which occurred in 
the aforementioned patient, was managed with 
drainage and reclosure and appeared to be healing 
at the time of death from Pseudomonas cepacia 
pneumonia. The pther infection was drained and is 
currently a small draining sinus. 
A more thorough analysis of the infectious com- 
plications after transplantation among our patients 
with CF has been published elsewhere. 28Surpris- 
ingly, infectious complications in CF recipients of 
lung transplants are no more prevalent than those 
found among recipients with other diagnoses of 
end-stage lung disease. 
Bronchiolitis obliterans is a major cause of late 
death in this series. To date, 15 patients have had 
clinical or pathologic 2i evidence of obliterative bron- 
chiolitis. Six of the 12 have died as a result of 
obliterative bronchiolitis, one underwent retrans- 
plantation but died 3 months later of CMV 
pneumonia, and one patient is awaiting retrans- 
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Fig. 3. Actuarial freedom from bronchiolitis obliterans syndrome (BOS) (grades I, II, and III), calculated 
according to the Kaplan-Meier method. Patients dying of causes other than bronchiolitis obliterans were 
treated as "withdrawn" for purposes of this analysis. (Data _+ 95% confidence limits.) 
plantation. For purposes of reporting, bronchiolitis 
obliterans yndrome has been classified according to 
clinical criteria, a9 Five of six patients who had grade 
III bronchiolitis obliterans yndrome ither died or 
were listed for retransplantation. Two of three pa- 
tients with grade II and one of two with grade I 
bronchiolitis obliterans yndrome died; noncompli- 
ance with medication contributed to the develop- 
ment of bronchiolitis obliterans yndrome in two 
patients who died. Four patients have shown evi- 
dence of obliterative bronchiolitis on transbronchial 
biopsy specimens with little or no decrement in 
FEV1; thus there are four patients with grade "zero- 
B" bronchiolitis obliterans yndrome. The actuarial 
freedom from development of clinically significant 
bronchiolitis obliterans yndrome (grades I to III) 
among our lung transplant recipients with CF is 
depicted in Fig. 3. No patients have had clinical 
evidence of bronchiolitis obliterans within 6 months 
of transplantation, but the risk of bronchiolitis ob- 
literans yndrome developing increases dramatically 
after 6 months. 
Postoperative FVC and FEV1 (expressed as per- 
cent predicted) are depicted in Fig. 4. Despite the 
inclusion of patients with known bronchiolitis oblit- 
erans, the postoperative spirometric data are en- 
couraging and have been associated with improve- 
ment in functional status. Six-minute walk data from 
patients who underwent ransplantation are de- 
picted in Fig. 5. Within 3 months of transplantation, 
80% of recipients have had New York class I 
functional status. 
Discussion 
The past decade has seen unsurpassed advances 
in the field of pulmonary transplantation. Since the 
first heart-lung transplantation, performed by Reitz 
and associates 3° in 1981, and the first successful 
single lung transplantation i 1983, 31 more than 
2000 lung or heart-lung transplant procedures 
have been reported to the Registry of The Inter- 
national Society of Heart and Lung Transplanta- 
tion. 32 
Patients with CF pose vexing problems to the 
transplant surgeon. These include the systemic ef- 
fects of chronic disease; the nutritional deficiency 
related to chronic infection and intestinal malab- 
sorption, with the concomitant difficulty of erratic 
absorption of lipid-soluble cyclosporine; and coloni- 
zation of the airway and sinuses with antibiotic- 
resistant strains of gram-negative organisms. Chronic 
pulmonary infection often results in the formation 
of dense pleural adhesions. These can also be the 
consequence of recurrent pneumothoraces, a com- 
mon problem in patients with CF, resulting in 
thoracostomy tube drainage, pleurodesis, pleurec- 
tomy, or pulmonary resection. Episodes of hemop- 
tysis may also have led to pulmonary resection or 
bronchial artery embolization. Hepatic dysfunction 
related to CF is common, renal insufficiency may be 
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Fig. 4. FVC and FEV1, expressed as percent predicted for CF lung transplant recipients at time of 
evaluation for transplantation (EVAL) and at intervals after transplantation. (Mean _+ standard error of 
the mean.) 
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Fig. 5. Distance walked in 6 minutes at time of evaluation for transplantation (EVAL), after ehabilitation 
(PRE-TX), and at intervals after transplantation. Improvement in performance was significant at each 
interval depicted (p < 0.05 by paired Student's t test). 
the sequela of aminoglycoside therapy of Pseudomo- 
nas infections, and glucose intolerance may be the 
result of endocrine pancreatic insufficiency. All of 
these problems may increase the risk of transplan- 
tation in these individuals. 
In other respects, patients with CF are potentially 
ideal candidates for lung transplantation. They are 
frequently oung, with life-threatening disease con- 
fined to one organ system. Even before the genetic 
defect was established, it was apparent hat the 
pulmonary epithelial abnormality of CF, evidenced 
by an altered potential difference, 3 was not mani- 
fested in the epithelium of heart-lung grafts in 
patients with CF. 33 This observation provided some 
assurance that the pulmonary abnormalities ob- 
served in patients with CF were unlikely to recur 
after transplantation. 
These problems have been responsible for a cau- 
tious approach to lung transplantation i  patients 
with CF. In 1990, Yacoub and colleagues 34from 
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Harefield reported 27 heart-lung transplants in pa- 
tients with CF over a 4-year period, with only four 
operative deaths and 1- and 2-year actuarial surviv- 
als of 78% and 72%, respectively. Papworth Hospi- 
tal, Cambridge, reported results of heart-lung trans- 
plantation in 32 patients with CF over a 5-year 
period, with five early deaths and a 1-year actuarial 
survival of 73%. 35 Heart-lung transplantation was 
initially applied to CF with discouraging results in 
North America, with a 42% 1-year actuarial survival 
reported from several centers urveyed, l° 
Noirclerc and coworkers 36 were the first to report 
on double lung transplantation for CF using a 
bibronchial anastomotic technique through a me- 
dian sternotomy with CPB. The next step in the 
evolution of the surgical technique was the "clam- 
shell" incision and the sequential lung transplanta- 
tion technique described by Pasque and col- 
leagues. 15 The University of Toronto outlined its 
3-year experience of double lung transplants in 17 
patients with CF, one having the "old" en bloc 
technique with a tracheal anastomosis, two with 
bibronchial anastomoses, and the most recent 14 
operated on by the sequential technique, with actu- 
arial survivals at 3 and 12 months of 66% and 58%, 
respectively. 37 Much of the mortality encountered in 
this series was related to infection with Pseudomo- 
nas cepacia. 
Shennib and associates 3  reported a 64% actuar- 
ial survival at t year in patients with CF undergoing 
double lung transplantation from two centers, one 
on either side of the Atlantic. Despite the potential 
for increased risk in this patient population, there is 
evidence that patients with CF have the same peri- 
operative and postoperative mortality as other pa- 
tients having lung transplantation, because actuarial 
survival reported to The International Society for 
Heart and Lung Transplant Registry is similar for 
patients with CF and other recipients of double lung 
transplants. 32 More recently, an updated report 
from Papworth Hospital has made the same obser- 
vation. 39 
Apart from the instances of documented cerebral 
damage (three cases), we have no explanation for 
the increased tendency for epilepsy to develop in 
our patients. Both cyclosporine and steroids can 
lower the seizure threshold; cyclosporine l vels have 
occasionally been high, and our routine use of 
ketoconazole to reduce cyclosporine metabolism 
may play a role. 
Although all prospective candidates are assessed 
by a clinical psychologist before transplantation, 
noncompliance has contributed to two deaths, and 
one other patient committed suicide despite good 
pulmonary function 8 months after transplantation. 
Undoubtedly, the stress associated with a chronic 
life-threatening illness contributes to morbidity and 
mortality in this patient population. 
Despite the morbidity associated with pulmonary 
transplantation i  patients with CF, we remain 
gratified by the well-documented improved pulmo- 
nary function and quality of life of the recipients, 
and we are pleased with the survival of this group of 
patients. We attribute this success to several factors. 
First, a team of surgeons, physicians, nurses, phys- 
iotherapists, and other health care workers has been 
assembled in an institution with considerable expe- 
rience in the management of patients with CF. We 
believe that a program of pulmonary rehabilitation 
is essential to prepare these debilitated patients for 
pulmonary transplantation. Our aggressive ap- 
proach to early postoperative extubation and ambu- 
lation is possible, we believe, only because of the 
rehabilitation program. 
Second, the evolution of the surgical technique of 
double lung transplantation has been instrumental 
in allowing for this degree of operative survival. The 
bilateral thoracotomy incision has dramatically im- 
proved intrathoracic exposure, rendering extraction 
of lungs from patients with CF safer than previous 
approaches through a sternotomy. Pleural adhesions 
in these patients are frequently numerous and vas- 
cular, and they can be divided, for the most part, 
under direct vision. A second advantage of the 
procedure, we believe, is the ability to avoid CPB in 
most cases, which in our experience has substantially 
reduced transfusion requirements and lung injury, 
shown by reduced postoperative ntilation require- 
ment in patients in whom CPB was avoided. This 
has recently been documented by Aeba and col- 
leagues. 4° We believe that these factors make iso- 
lated lung transplantation the procedure of choice 
for patients with CF, rather than the so-called 
"domino procedure," wherein the recipient of a 
heart-lung raft provides a donor heart to another 
recipient. 34 It is irrational to replace the heart of a 
patient with CF unless there is a concomitant severe 
degree of biventricular cardiac failure. 
Three pressing problems facing lung transplanta- 
tion today are the scarcity of suitable pulmonary 
donors, early graft dysfunction, and the develop- 
ment of bronchiolitis obliterans, leading to organ 
failure in many recipients. The organ donor short- 
age may ultimately be solved by the use of xe- 
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nografts, although current understanding of immu- 
nology precludes this. The use of bilobar transplants 
from living related donors has been proposed, and a 
small experience exists with this strategy for patients 
with CF, 41 but this option may be impractical for 
many adults with CF. The use of circulation-arrested 
cadavers may increase the donor pool and may be a 
particularly attractive option for lung transplanta- 
tion programs. 42 
Bronchiolitis obliterans is a poorly understood 
process that is prevalent after heart-lung or isolated 
lung transplantation. Evidence is mounting that the 
process is an immunologic one, but there is a 
plethora of predisposing risk factors, including viral 
infection. Response to augmented immunosuppres- 
sion is inconsistent. 43Retransplantation forpatients 
with end-stage bronchiolitis obliterans is controver- 
sial, because the outcome of retransplantation is 
poor for lung transplant recipients. 44 
This report documents that isolated lung trans- 
plantation can be undertaken with acceptable mor- 
tality in patients with CF, despite the potential for 
increased risks in these patients. 
We thank Betsy Mann for editorial assistance in the 
preparation of this manuscript and acknowledge the su- 
perb patient care given by the nursing, physiotherapy, and 
medical staffs of University of North Carolina Hospitals to 
patients with this challenging disease. Dr. Egan also 
acknowledges the expert clinical advice given by Dr. J. 
Cooper, Dr. M. Noirclerc, Mr. J. Wallwork, and Dr. T. 
Winton. 
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Discussion 
Dr. Alec Patterson (St. Louis, Mo.). Dr. Egan, you and 
your colleagues are to be congratulated for a remarkable 
achievement to conduct hat number of transplants in a 
group of patients with CF. They are the most difficult 
group of patients that we are asked to see for transplan- 
tation. We reported asmaller experience several years ago 
from Toronto with much less impressive results than you 
have described. 
You mentioned that 18 patients died on the waiting list. 
What percentage ofyour waiting list do these 18 patients 
represent? Do you have any sense of how long the wait for 
a donor is, both for those who died and those who 
underwent the transplant operation? 
I would appreciate your thoughts about the use of 
alternate strategies to get these patients to transplanta- 
tion. What are your comments about lobar transplanta- 
tion? Perhaps Dr. Statues might want to comment on this 
specific subject. Pulmonary bipartition is another interest- 
ing strategy. I would also appreciate your comments as to 
whether these patients hould be stratified on the waiting 
list so as to achieve transplantation more often in those 
patients who have the highest mortality rate. 
Dr. Egan. The contribution that you and the group from 
the University of Toronto made for transplantation i  
patients with CF is widely recognized. I think it is fair to 
say that the group in Toronto was cursed with a popula- 
tion of patients in whom Pseudomonas cepacia was very 
prevalent. This is a nasty organism that is difficult to treat. 
In fact, much of the morbidity and mortality in the series 
that you allude to from Toronto was related to problems 
with Pseudomonas cepacia. 
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As I mentioned, 18 patients have died on our waiting 
list. The difference between patients who died and pa- 
tients who were able to survive long enough to undergo 
transplantation was that the patients who died waiting 
were generally sicker at the time of referral. Their FEV 1 
was significantly lower than that of the transplanted 
patients, who had an average FEV1 of 20% predicted at 
the time of their transplantation. 
Lobar transplantation is an interesting solution to the 
problem of death on the waiting list. It will be applicable 
to some patients, but size discrepancies, blood incompat- 
ibilities, and other potential problems are going to limit its 
applicability to all patients with CF. I am intrigued by the 
notion of splitting a lung and servicing a patient with two 
half lungs, and ! think that is one strategy that merits 
further study. 
It is a shame that in this country we are not identifying 
all potential donors. In particular, we are not identifying 
and distributing all lungs from donors that become iden- 
tified. I think that the United Network for Organ Sharing 
should look very seriously at the amount of time that 
patients have to wait for lungs and what is happening to 
lungs that are not being transplanted. 
Finally, we are attempting to address the donor short- 
age in our laboratory. We believe that it may be possible 
to retrieve lungs from circulation-arrested cadavers for 
transplantation. 
Dr. John R. Benfield (Sacramento, Calif.). Is it a correct 
recollection from your slides that the ischemic time for the 
second donor lung was unusually long? If that is a correct 
observation, would you comment on some of the factors 
that contribute to that? Do you think that may have 
contributed to your early graft failure? 
Dr, Egan. We do not know the upper limit for ischemic 
time. The intent is to try to keep it as short as possible, but 
the extraction of these lungs can be very difficult. If the 
donor lungs arrive in the operating room before we are 
quite ready for them, that is, before we have done the 
dissection on both sides, we will transplant the side that 
we are ready to do and then extract he lung on the other 
side. This program has also developed a transplant fellow- 
ship, and we have a responsibility o train other surgeons 
in the surgical technique. That adds a little time to each 
transplant procedure. However, we have been fortunate 
that the long ischemic times have not translated into poor 
pulmonary function. In fact, one of the patients who 
required retransplantation had one of the shortest isch- 
emic times of any of our patients. 
Mr. All Rahman (Manchester, England). We do not see 
any need for using omentum, we had no problems at all 
with dehiscence, and we use bypass in all double lung 
transplants, which shortens the operating time. One of our 
biggest problems is that we are pressured by the chest 
physicians wanting us to operate on patients with CF. 
After our first few successes they moved the CF unit right 
to the doorstep of the surgical ward. Thus I would like to 
direct my questions to the selection process, because it is 
a problem. First, do you operate on patients with totally 
resistant Pseudomonas cepacia? Second, I noticed that 
many of your patients have Aspergillus infection after the 
operation. Third, do you ignore CMV compatibility be- 
cause of the shortage of donors? I notice that you had 27 
cases of CMV infection afterward. 
Dr. Egan. The issue of pan-resistant Pseudomonas i
difficult to deal with. Even though Pseudomonas cepacia 
may start out being susceptible, it frequently becomes 
pan-resistant. We have not listed patients who had pan- 
resistant Pseudomonas, and to my knowledge none of our 
patients has had pan-resistant Pseudomonas tthe time of 
transplantation. On two occasions, however, the organism 
became pan-resistant after transplantation, and this was 
lethal in both instances. 
We do see Aspergillus frequently in cultures before 
transplantation. I believe one of the reasons we have not 
had significant postoperative problems with Aspergillus or 
Candida is that we avoid systemic steroids in these pa- 
tients for the first 2 weeks. Although there is some 
discussion about whether that is beneficial for airway 
healing, I think it does change the flora in the upper 
airway and may contribute to morbidity in other arenas. 
With respect to CMV, we will cross CMV barriers 
because of the shortage of donors. Recently we stopped 
giving all patients 2 weeks of ganciclovir prophylaxis, 
because our data did not indicate that that conferred any 
benefit. We will, however, use gancMovir prophylaxis in 
mismatched patients for 4 weeks and treat them with 
hyperimmune CMV globulin. That strategy has resulted in 
an incidence of CMV pneumonia nd CMV disease that is 
high but that has been responsible for only one death so 
far. 
Dr. Vanghn A. Starnes (Los Angeles, Calif.). To give 
some follow-up on the lobar alternative strategies that can 
be used successfully, we have performed transplantation 
in seven patients with CF, with early survival in all. The 
real issue in those patients is that we do use CPB because 
we have been concerned about all the cardiac output 
flowing through that one lobar segment while the other is 
being transplanted. This is the only modification of the 
existing transplant technique that I would suggest might 
be important. In addition, with the introduction of apro- 
tinin, we have been able to significantly reduce our use of 
blood after the operation. 
